Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study

PURPOSE: Combination treatment with immune checkpoint inhibitors has shown enhanced antitumor activity compared with monotherapy in tumor types such as melanoma. The open-label, parallel-cohort, dose-escalation, phase I CheckMate 016 study evaluated the efficacy and safety of nivolumab plus ipilimum...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Clin Oncol
Glavni autori: Hammers, Hans J., Plimack, Elizabeth R., Infante, Jeffrey R., Rini, Brian I., McDermott, David F., Lewis, Lionel D., Voss, Martin H., Sharma, Padmanee, Pal, Sumanta K., Razak, Albiruni R. Abdul, Kollmannsberger, Christian, Heng, Daniel Y.C., Spratlin, Jennifer, McHenry, M. Brent, Amin, Asim
Format: Artigo
Jezik:Inglês
Izdano: American Society of Clinical Oncology 2017
Teme:
ORIGINAL REPORTS
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7587408/
https://ncbi.nlm.nih.gov/pubmed/28678668
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2016.72.1985
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items